Edition:
United States

Intellipharmaceutics International Inc (IPCI.OQ)

IPCI.OQ on NASDAQ Stock Exchange Capital Market

2.61USD
4:00pm EDT
Change (% chg)

$-0.12 (-4.40%)
Prev Close
$2.73
Open
$2.73
Day's High
$2.73
Day's Low
$2.35
Volume
5,357
Avg. Vol
4,112
52-wk High
$12.50
52-wk Low
$2.30

Latest Key Developments (Source: Significant Developments)

Intellipharmaceutics Files For Resale Of Up To 6.86 Mln Shares By Selling Shareholders
Thursday, 19 Jul 2018 06:25am EDT 

July 19 (Reuters) - Intellipharmaceutics International Inc ::INTELLIPHARMACEUTICS INTERNATIONAL INC FILES FOR RESALE OF UP TO 6.86 MILLION COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING.  Full Article

Anson Funds Reports 7.2 Pct Passive Stake In Intellipharmaceutics
Tuesday, 20 Mar 2018 04:50pm EDT 

March 20 (Reuters) - Anson Funds Management Lp :ANSON FUNDS MANAGEMENT LP REPORTS 7.2 PERCENT PASSIVE STAKE IN INTELLIPHARMACEUTICS INTERNATIONAL INC AS OF MARCH 14, 2018 - SEC FILING‍​.  Full Article

Intellipharmaceutics Meets With FDA Regarding Oxycodone Er NDA Development Program
Friday, 9 Feb 2018 08:32am EST 

Feb 9 (Reuters) - Intellipharmaceutics International Inc ::INTELLIPHARMACEUTICS MEETS WITH FDA REGARDING OXYCODONE ER NDA DEVELOPMENT PROGRAM.INTELLIPHARMACEUTICS INTERNATIONAL - BASED ON MEETING WITH FDA, OXYCODONE ER WILL NO LONGER INCLUDE THE BLUE DYE IN IT.INTELLIPHARMACEUTICS INTERNATIONAL- FDA CONFIRMED REMOVAL OF BLUE DYE IN OXYCODONE ER UNLIKELY TO HAVE IMPACT ON ITS FORMULATION QUALITY, PERFORMANCE.INTELLIPHARMACEUTICS INTERNATIONAL - WILL NOT BE REQUIRED TO REPEAT IN VIVO BIOEQUIVALENCE STUDIES & PHARMACOKINETIC STUDIES SUBMITTED IN OXYCODONE ER NDA.INTELLIPHARMACEUTICS - FDA SAID, FROM ABUSE LIABILITY PERSPECTIVE,CATEGORY 1 STUDIES WILL NOT HAVE TO BE REPEATED ON OXYCODONE ER WITHOUT BLUE DYE.  Full Article

‍Armistice Capital​ Reports 5.2 Pct Passive Stake In Intellipharmaceutics International
Monday, 4 Dec 2017 05:34pm EST 

Dec 4 (Reuters) - Intellipharmaceutics International Inc ::‍ARMISTICE CAPITAL LLC​ REPORTS A 5.2 PERCENT PASSIVE STAKE IN INTELLIPHARMACEUTICS INTERNATIONAL INC AS OF NOV 22 - SEC FILING.  Full Article

Intellipharmaceutics launches additional strengths of generic Focalin XR in U.S.​
Thursday, 30 Nov 2017 10:44am EST 

Nov 30 (Reuters) - Intellipharmaceutics International Inc ::SAYS ‍LAUNCHED 5&40 MG STRENGTHS OF ITS GENERIC FOCALIN XR CAPSULES IN U.S​.SAYS UNDER DEAL BETWEEN CO & PAR, CO RECEIVES QTRLY PROFIT-SHARE PAYMENTS ON PAR'S U.S. SALES OF GENERIC FOCALIN XR.  Full Article

Intellipharmaceutics announces US$4 mln registered direct offering
Wednesday, 11 Oct 2017 08:00am EDT 

Oct 11 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics announces US$4 million registered direct offering.Intellipharmaceutics - ‍entered securities purchase agreements with investors providing for purchase ,sale of 3.6 million shares at US$1.10 per share​.  Full Article

Intellipharmaceutics- Q3 loss per share $0.08
Tuesday, 10 Oct 2017 05:20pm EDT 

Oct 10 (Reuters) - Intellipharmaceutics International Inc :Intellipharmaceutics announces third quarter 2017 results.Q3 loss per share $0.08.Q3 revenue $1.2 million versus $600,000.Intellipharmaceutics International Inc - ‍ expects revenue from generic Seroquel XR to increase going forward​.  Full Article

Intellipharmaceutics receives complete response letter from FDA for Rexista NDA
Monday, 25 Sep 2017 07:00am EDT 

Sept 25 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics receives complete response letter from the FDA for rexista™ NDA.Intellipharmaceutics receives complete response letter from the fda for rexista™ NDA.Intellipharmaceutics International Inc - ‍Intellipharmaceutics has been given one year to respond to CRL, and can request additional time if necessary.Intellipharmaceutics international inc - ‍fda has also requested that Intellipharmaceutics submit an alternate proposed proprietary name for oxycodone ER​.Intellipharmaceutics -do not expect additional category 2, 3 studies FDA requested will impact anticipated commercialization timeline for oxycodone ER​.  Full Article

Intellipharmaceutics provides operational update on its Rexista(TM) program
Tuesday, 5 Sep 2017 02:35pm EDT 

Sept 5 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics provides operational update.Currently anticipate Rexista program​ study will take nine months from commencement to complete.Is in process of commencing its planned Category 3 study to support certain label claims for Rexista(TM)​.Trial date for previously announced patent litigation by Purdue against co regarding Rexista(TM) set for Oct 22, 2018​.‍FDA is stayed from granting approval of Rexista until August 24, 2019​.  Full Article

Intellipharmaceutics announces resignation of CFO
Tuesday, 8 Aug 2017 03:00pm EDT 

Aug 8 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics announces resignation of chief financial officer.Says ‍commenced a search to fill Della Penna's role​.Says ‍announced resignation of Domenic Della Penna, chief financial officer, who is leaving company effective Sept 1.Says ‍pending hiring of replacement for Penna, functions of CFO will be carried out by Amina Odidi​.  Full Article

BRIEF-Intellipharmaceutics Received Notice From Nasdaq Hearings Panel

* INTELLIPHARMACEUTICS INTERNATIONAL - RECEIVED NOTICE FROM NASDAQ HEARINGS PANEL GRANTING REQUEST FOR CONTINUED LISTING UNTIL SEPT 28, 2018 Source text: (https://bit.ly/2rZpVwr) Further company coverage: